Results 141 to 150 of about 2,808,349 (298)

Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus‐1 (HIV‐1): A systematic literature review of clinical and patient‐reported outcomes

HIV Medicine, EarlyView.
Abstract Background Treatment guidelines recommend rapid antiretroviral therapy (ART) initiation among eligible people with HIV to improve treatment outcomes and reduce HIV transmission. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), an integrase strand transfer inhibitor‐based single‐tablet regimen, is recommended for rapid start in US and
Jade Ghosn, Jeremy Chow, Monica Gandhi, Miguel Górgolas, Aws Al‐Hayani, Hansel Tookes, Max Lee, Emily F. Kaiser, David Malebranche, Fernando Alvarez Bognar, Bhumi Gandhi‐Patel, Lili Dai   +11 more
wiley   +1 more source

Computational structure‐based drug design: Predicting target flexibility [PDF]

, 2018
The role of molecular modeling in drug design has experienced a significant revamp in the last decade. The increase in computational resources and molecular models, along with software developments, is finally introducing a competitive advantage in early
Ding X., Dreher J., Khago D., Li Y., Samuel G.   +4 more
core   +2 more sources

Exploring the untapped potential of single‐cell and spatial omics in plant biology

New Phytologist, EarlyView.
Summary Advances in single‐cell and spatial omics technologies have revolutionised biology by revealing the diverse molecular states of individual cells and their spatial organization within tissues. The field of plant biology has widely adopted single‐cell transcriptome and chromatin accessibility profiling and spatial transcriptomics, which extend ...
Tatsuya Nobori
wiley   +1 more source

CD8+ T lymphocyte responses target functionally important regions of Protease and Integrase in HIV-1 infected subjects

Journal of Translational Medicine, 2004
Background CD8+ T cell responses are known to be important to the control of HIV-1 infection. While responses to reverse transcriptase and most structural and accessory proteins have been extensively studied, CD8 T cell responses specifically directed to
Yu Xu G, Fitzpatrick Cecily A, Rathod Almas, Addo Marylyn M, Rodriguez William R, Perkins Beth, Rosenberg Eric S, Altfeld Marcus, Walker Bruce D   +8 more
doaj   +1 more source

Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.

Journal of Infectious Diseases, 2015
BACKGROUND Little is known about how different antiretrovirals effect inflammation and monocyte activation in human immunodeficiency virus (HIV) infection.
Corrilynn O Hileman, B. Kinley, V. Scharen-Guivel, K. Melbourne, J. Szwarcberg, Janet K Robinson, M. Lederman, G. McComsey   +7 more
semanticscholar   +1 more source

Angiotensin II Type 1 Receptor Blocker Usage Prevents Oxidative Stress and Muscle Dysfunction in HIV

Fundamental &Clinical Pharmacology, Volume 39, Issue 4, August 2025.
ABSTRACT Background We aimed to elucidate the role of Angiotensin II type 1 receptor (AT1R) blocker usage in muscle wasting and dysfunction related to HIV. Research Design and Methods Appendicular skeletal muscle mass, higher and lower limb strength, and physical fitness were determined in people living with HIV (PWH) using AT1R blockers users (n = 33),
Rafael Deminice, Paola Sanches Cella, Ana Lúcia Borsari, Camila S. Padilha, Vitor Hugo Fernando de Oliveira   +4 more
wiley   +1 more source

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection

Infection and Drug Resistance, 2010
Lisa M Chirch, Roy T SteigbigelDivision of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USAAbstract: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a ...
Lisa M Chirch, Roy T Steigbigel
doaj  

Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: Subtype G is a circulating recombinant form [PDF]

, 2007
Human immunodeficiency virus type I (HIV-1) is classified in nine subtypes (A to D, F, G, H, J, and K), a number of subsubtypes, and several circulating recombinant forms (CRFs).
Abecasis, Ana B., Camacho, Ricardo, de Oliveira, Tulio, Lemey, Philippe, Peeters, Martine, Rambaut, Andrew, Shapiro, Beth, Vandamme, Anne-Mieke, Vidal, Nicole   +8 more
core   +2 more sources

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV

Clinical Pharmacology in Drug Development, Volume 14, Issue 7, Page 528-541, July 2025.
Abstract Long‐acting (LA) cabotegravir 200‐mg/mL (CAB200) injections are approved for HIV‐1 prevention and as a complete LA HIV‐1 treatment regimen with rilpivirine. A high‐concentration suspension formulation, cabotegravir 400 mg/mL (CAB400‐D), was developed to enable less frequent dosing and self‐administration. This phase 1, double‐blind, randomized
Kelong Han, Paul Benn, Jörg Sievers, David Dorey, Michael Warwick‐Sanders, Randa Hareedy, Louise Harkness, Claudia Leemereise, Kjersten Offenbecker, Christina Donatti, Darin B. Brimhall, Christian Schwabe, Craig Boyle, Michael A. Hassman, Steve Knowles, Ronald D'Amico, William R. Spreen   +16 more
wiley   +1 more source

Design, synthesis, molecular dynamics studies and biological evaluations of 4-hydroxy-5-pyrrolinone-3-carbohydrazides as HIV-1 integrase inhibitors

European Journal of Medicinal Chemistry Reports
Acquired immune deficiency syndrome (AIDS) diseases despite the efficacy of anti-HIV therapy, remain one of the human's most serious problems. Hence, the introduction of novel anti-HIV agents as first-line therapy is still required. HIV integrase lacking
Nafiseh Karimi, Amirreza Dowlati Beirami, Rouhollah Vahabpour Roudsari, Zahra Hajimahdi, Afshin Zarghi   +4 more
doaj